BioMerieux exceeds expectations during second quarter of 2017

BioMerieux has announced its financial results for the second quarter of 2017, during which it delivered a sales total of 1.13 billion euros (871.5 million pounds).

This represents a year-on-year increase of 13.3 percent on a reported basis, which was a better margin of growth than the company had predicted for the period. This was driven by a particularly strong performance in the Americas.

The success of the company's FilmArray brand and the fast-paced growth of its microbiology lines were both cited as key drivers of momentum, as well as robust results in Asia Pacific and the Europe, Middle East and Africa regions, with all strategic lines performing well.

Key highlights of the quarter include the receipt of European and US regulatory approval of its FilmArray RP2plus and RP2 respiratory panels, in addition to the securing of US clearance for Rapidec Carba NP, a medical test used to confirm the detection of carbapenemase-producing bacteria in agar cultures.

Alexandre Merieux, chief executive officer of BioMerieux, said: "In light of this better-than-anticipated performance, we expect to achieve the higher end of our target organic sales growth range for the full year."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.